AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03933501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
Study NCT00600002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
Study NCT04611477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice Hulk
Description: Placebo
Study NCT04611477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic365 Ver 5
Description: Active Comparator
Study NCT04611477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic365 Ver 7
Description: Active Comparator
Study NCT02169076 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cardiac Resynchronization Therapy
Description: The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
Study NCT02169076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy
Description: The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
Study NCT01789879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
Study NCT01789879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
Study NCT01789879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
Study NCT01927458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
Study NCT04248777 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standardised OCT-guided intervention
Description: The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
Study NCT03938246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 25 mg (US)
Description: Oral dose, tablet, daily dosing
Study NCT03938246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 50 mg (US)
Description: Oral dose, tablet, daily dosing
Study NCT03938246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (US)
Description: Oral dose, tablet, daily dosing
Study NCT03938246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 50 mg (China)
Description: Oral dose, tablet, daily dosing
Study NCT03938246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (China)
Description: Oral dose, tablet, daily dosing
Study NCT03938246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 75 mg (US)
Description: Oral dose, tablet, daily dosing
Study NCT04284319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCD Heart Transplantation Using NRP
Description: Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
Study NCT01787565 — intervention group
Intervention type: OTHER
Intervention: painPREMIER cohort
Description: Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
Study NCT01787565 — intervention group
Intervention type: OTHER
Intervention: Control cohort
Description: A matched group of low back pain patients not managed with painPREMIER.
Study NCT01838681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, tablets, orally
Study NCT01838681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
Study NCT01838681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
Study NCT01838681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADT
Description: Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
Study NCT04363554 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fluid intake
Description: The participants will intake fluid
Study NCT04363554 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thirsting
Description: The participants will thirst
Study NCT02016274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy
Description: Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
Study NCT01406353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Mitral Commissurotomy
Description: Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
Study NCT00298415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin
Description: Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
Study NCT00298415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy (gemcitabine or vinorelbine)
Description: Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
Study NCT02067611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: Parallel Assignment
Study NCT02067611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment
Study NCT01852487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400mg /day during 6 months
Study NCT03340623 — intervention group
Intervention type: DEVICE
Intervention: Venous coupler
Description: A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
Study NCT00815087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: 15 sessions of VitalStim® therapy, 60 minutes per session
Study NCT00815087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise home program
Description: Daily exercise training
Study NCT04913974 — intervention group
Intervention type: PROCEDURE
Intervention: Uni-condylar knee arthroplasty
Description: Surgical replacement of medial compartment of arthritic knee with an implant
Study NCT06603532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-load blood flow restriction (BFR) training
Description: The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in the BFR group exercised with blood flow restriction caused by an inflatable cuff placed on the proximal part of the thigh and inflated to 120-140 mmHg. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
Study NCT06603532 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: low-load resistance training
Description: The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in SHAM-BFR group performed an identical exercise protocol as experimental (BFR) group, while having thigh cuff inflated to only 20 mmHg, which did not affect normal muscle blood flow. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
Study NCT03333538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEvac-Lyo (component A)
Description: Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component A
Study NCT03333538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccination
Study NCT03333538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEvac-Lyo (component B)
Description: Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component B
Study NCT03333538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEvac-Lyo
Description: Biological: GamEvac-Lyo (vaccine) vaccination, therapeutic scheme: the sequential introduction of components A and b with an interval of 21 days
Study NCT00711568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: 20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)
Study NCT00711568 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: 20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli
Study NCT00711568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulator
Description: Repetitive Transcranial Magnetic Stimulator
Study NCT02828501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
Study NCT01145222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C. CNS 7056
Description: Initial high dose plus supplemental doses as necessary.
Study NCT01145222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D. Midazolam
Description: Initial standardized dose plus supplemental doses as necessary.
Study NCT02100917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMB-3111
Study NCT02100917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Study NCT01913405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant factor VIII (rFVIII)
Description: Lyophilized powder and solvent for solution for injection
Study NCT02343328 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplant
Study NCT02343328 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplant
Study NCT02343328 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02343328 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01967953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLP Group
Description: EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.~Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
Study NCT03640182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health management model of TCM preventive medicine
Description: The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
Study NCT00508300 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epidural analgesia
Description: Thoracic epidural analgesia until day 2
Study NCT00508300 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Patient controlled analgesia
Description: Patient controlled analgesia (morphine-based)
Study NCT00132483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instruction in physical training program
Description: Instruction in physical training program.
Study NCT02715752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Gene-Eden-VIR/Novirin
Study NCT04352660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C injection
Description: MMC delivered by preoperative subconjunctival injection
Study NCT04352660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C sponge
Description: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Study NCT04425850 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)
Description: Topical application in the nose and oral cavity
Study NCT00545805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass plus total omentectomy
Description: Roux-en-Y Gastric Bypass plus total omentectomy
Study NCT00545805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass
Description: Roux-en-Y Gastric Bypass without omentectomy
Study NCT01746056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive Heat Patch
Description: The heat patch will be applied for 2 hours every day for a period of 12 weeks.
Study NCT02995720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine combination drug, Rosuvastatin
Study NCT02995720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan/Amlodipine combination drug, Rosuvastatin
Study NCT03923660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental Concentric-eccentric exercise test
Description: Patients will perform incremental exercise test on semi recumbent eccentric ergometer
Study NCT03923660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental Eccentric-concentric exercise test
Description: Patients will perform incremental exercise test on semi recumbent concentric ergometer
Study NCT03094598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leaflet
Description: The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).
Study NCT03094598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure
Description: The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).
Study NCT03094598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
Study NCT00428298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Subjects take two 500 mg capsules twice daily for 16 weeks.
Study NCT01009112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD + IRT/CBT-I
Description: 6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
Study NCT01009112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD + Supportive Care Therapy
Description: 6 weeks of prolonged exposure + 12 weeks of supportive care therapy
Study NCT01009112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD + Supportive Care Therapy
Description: 6 weeks of prolonged exposure + 12 weeks of supportive care therapy
Study NCT01166269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: phleum pratense (grass-allergen)
Description: 6 injections of grass-allergen. Every dose will be 1000 SQ-U.
Study NCT01166269 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: phleum pratense (grass allergen)
Description: 3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
Study NCT01166269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: 6 injections of placebo (physiological saline)in a lymph node.
Study NCT00005963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00005963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00643045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Study NCT02614014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior interventional program
Study NCT01623752 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study NCT01814332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679, oral administration, 350mg/day, 6 week administration
Study NCT01814332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo compound treatment for comparison with IP
Study NCT03233685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Training
Description: The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
Study NCT00799175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorolac and epinephrine
Description: In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
Study NCT00799175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
Study NCT00643045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02559505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.25 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
Study NCT02559505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural influenza infection
Description: Children enrolled on presentation to their primary care provider with a natural influenza infection
Study NCT02559505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.5 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
Study NCT02537860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block injections from T12 to L2
Description: Three anesthetic injections are done
Study NCT03233685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Training
Description: Normal training routine